Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib and Keytruda in recurrent or metastatic HNSCC
NCT03695510Phase 2Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Jan 2019
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of afatinib and pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by National Taiwan University Hospital. Primary endpoint: Objective Response Rate at 2 years. Started Jan 2019; status: completed.
02
Drugs
afatinibpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03695510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03695510.